HomeAI · summaries
Storia in 4 fonti
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s Association International Conference.Intravenous lecanemab (Leqembi, Eisai) has yielded substantial reductions in amyloids and significantly slower clinical decline, Michael Irizarry, MD, MPH, senior vice
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s…
- ·
markets.businessinsider.com
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London ...
